JP2016530284A5 - - Google Patents

Download PDF

Info

Publication number
JP2016530284A5
JP2016530284A5 JP2016539022A JP2016539022A JP2016530284A5 JP 2016530284 A5 JP2016530284 A5 JP 2016530284A5 JP 2016539022 A JP2016539022 A JP 2016539022A JP 2016539022 A JP2016539022 A JP 2016539022A JP 2016530284 A5 JP2016530284 A5 JP 2016530284A5
Authority
JP
Japan
Prior art keywords
peg
agent
drug
average
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016539022A
Other languages
English (en)
Japanese (ja)
Other versions
JP6509867B2 (ja
JP2016530284A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/052638 external-priority patent/WO2015031316A1/en
Publication of JP2016530284A publication Critical patent/JP2016530284A/ja
Publication of JP2016530284A5 publication Critical patent/JP2016530284A5/ja
Application granted granted Critical
Publication of JP6509867B2 publication Critical patent/JP6509867B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016539022A 2013-08-30 2014-08-26 疾患及び障害を治療するためにインターロイキン−10を使用する方法 Expired - Fee Related JP6509867B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361872394P 2013-08-30 2013-08-30
US61/872,394 2013-08-30
PCT/US2014/052638 WO2015031316A1 (en) 2013-08-30 2014-08-26 Methods of using interleukin-10 for treating diseases and disorders

Publications (3)

Publication Number Publication Date
JP2016530284A JP2016530284A (ja) 2016-09-29
JP2016530284A5 true JP2016530284A5 (enExample) 2017-10-05
JP6509867B2 JP6509867B2 (ja) 2019-05-08

Family

ID=52587254

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016539022A Expired - Fee Related JP6509867B2 (ja) 2013-08-30 2014-08-26 疾患及び障害を治療するためにインターロイキン−10を使用する方法

Country Status (8)

Country Link
US (2) US10010588B2 (enExample)
EP (1) EP3038642A4 (enExample)
JP (1) JP6509867B2 (enExample)
CN (1) CN105658232A (enExample)
AU (1) AU2014311432A1 (enExample)
CA (1) CA2920679A1 (enExample)
HK (1) HK1226308A1 (enExample)
WO (1) WO2015031316A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
ES2941234T3 (es) 2014-10-22 2023-05-19 Armo Biosciences Inc Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
US11136362B2 (en) * 2016-03-10 2021-10-05 The Board Of Trustees Of The Leland Stanford Junior University Peptide modulators of specific calcineurin protein-protein interactions
RS66416B1 (sr) 2019-01-18 2025-02-28 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluorometoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i metode njegove primene
WO2020176478A1 (en) 2019-02-25 2020-09-03 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
WO2022150788A2 (en) 2021-01-11 2022-07-14 Synthekine, Inc. Compositions and methods related to receptor pairing

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63152393A (ja) 1986-07-03 1988-06-24 Takeda Chem Ind Ltd グリコシル誘導体
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US5231012A (en) 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
IE68836B1 (en) 1991-01-16 1996-07-10 Schering Corp Use of interleukin-10 in adoptive immunotherapy of cancer
JP3260368B2 (ja) 1991-01-16 2002-02-25 シェリング・コーポレーション インターロイキン−10による腫瘍性疾患の処置
US5624823A (en) 1991-11-22 1997-04-29 The General Hospital Corporation DNA encoding procine interleukin-10
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1994004180A2 (en) 1992-08-20 1994-03-03 Schering Corporation Novel uses of il-4 and/or il-10, and antibodies against the same
AU6000894A (en) 1993-02-01 1994-08-29 Michel Goldman Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
US5328989A (en) 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
US5665345A (en) 1993-05-24 1997-09-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of inhibiting viral replication using IL-10
HUT73463A (en) 1993-07-26 1996-08-28 Schering Corp Agonists and antagonists of human interleukin-10
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
CN1142186A (zh) 1994-01-20 1997-02-05 先灵公司 用白介素-10激活外周血单核细胞的细胞溶解活性
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5866134A (en) 1995-03-24 1999-02-02 Schering Corporation Method for enhancing the antibody response to specific antigens with Interleukin-10
US5770190A (en) 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5945097A (en) * 1996-09-06 1999-08-31 Schering Corporation Method for lowering cholesterol levels with interleukin-10
EP0925072A2 (en) * 1996-09-06 1999-06-30 Schering Corporation Method for lowering cholesterol levels
US5989867A (en) 1996-09-23 1999-11-23 Knappe; Andrea DNA encoding IL-10-like homologue; related reagents
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US6428985B1 (en) 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
AU2158000A (en) 1998-12-22 2000-07-12 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
WO2001005821A2 (en) 1999-07-16 2001-01-25 Maria Teresa Bejarano Viral il-10 for the inhibition of angiogenesis, tumorigenesis and metastasis
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
AU2001231532A1 (en) 2000-02-11 2001-08-20 Maxygen Aps Improved interleukin 10
US20030186386A1 (en) 2000-02-11 2003-10-02 Hansen Christian Karsten Interleukin 10
WO2002026265A2 (en) 2000-09-29 2002-04-04 Schering Corporation Pegylated interleukin-10
JP2002142770A (ja) 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
EP1234583A1 (en) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
GB0212648D0 (en) 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
AU2003280315A1 (en) 2002-11-14 2004-06-03 Maxygen, Inc. Conjugates of interleukin-10 and polymers
DK1565183T3 (da) 2002-11-29 2008-12-01 Maria Grazia Roncarolo Rapamycin og IL-10 til behandling af autoimmune sygdomme
AU2003303222A1 (en) 2002-12-19 2004-07-14 Universiteit Gent Mutant proteins showing increased secretion
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
PL396711A1 (pl) 2002-12-26 2011-12-19 Mountain View Pharmaceuticals, Inc. Koniugaty polimerów z cytokinami, chemokinami, czynnikami wzrostu, hormonami polipeptydowymi i ich antagonistami, kompozycja farmaceutyczna i sposób zapobiegania, diagnozowania lub leczenia
US20050214859A1 (en) 2003-03-03 2005-09-29 Dyax Corp. Peptides that specifically bind HGF receptor (cMet) and uses thereof
EP2261244A3 (en) 2003-04-15 2011-02-23 Glaxosmithkline LLC Human il-18 substitution mutants and their conjugates
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
DE602004025509D1 (de) 2003-11-28 2010-03-25 Univ Sydney Virales latentphasen-interleukin-10-(vii-10) und verwendungen davon
CA2558738C (en) 2004-03-11 2013-02-05 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
PT2409713E (pt) 2004-08-10 2015-10-09 Genzyme Corp Oligonucleótidos para utilização em modulação dos níveis de lipoproteínas e colesterol em humanos
US20060046961A1 (en) 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
CN100334112C (zh) 2004-10-15 2007-08-29 上海海欣生物技术有限公司 人白细胞介素15与Fc融合蛋白
GB0500643D0 (en) 2005-01-13 2005-02-23 Renovo Ltd Medicaments
UY29460A1 (es) 2005-04-08 2006-11-30 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
WO2006119170A2 (en) 2005-05-02 2006-11-09 Avigen, Inc. Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
JP4992025B2 (ja) 2005-05-31 2012-08-08 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト 変異体il−10
CA2655511C (en) 2005-07-01 2017-03-21 John Schrader Methods of isolating cells and generating monoclonal antibodies
DE602006018969D1 (de) 2005-10-04 2011-01-27 Bristol Myers Squibb Co Herstellung und reinigung von il-29
US7939056B2 (en) 2005-11-14 2011-05-10 The Brigham And Women's Hospital, Inc. Interleukin-10 compositions for the treatment of adenocarcinomas
WO2007087576A2 (en) 2006-01-24 2007-08-02 The Uab Research Foundation Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases
KR20090027693A (ko) 2006-05-31 2009-03-17 디나벡크 가부시키가이샤 알츠하이머병 치료제
WO2008054585A2 (en) 2006-09-28 2008-05-08 Schering Corporation Use of pegylated il-10 to treat cancer
JP2010506166A (ja) 2006-10-05 2010-02-25 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ デング熱の診断及び治療
CA2708004C (en) 2006-12-04 2015-12-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
WO2008089491A2 (en) 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
AU2008281913B2 (en) 2007-07-31 2013-11-07 Affibody Ab New albumin binding compositions, methods and uses
WO2009036568A1 (en) 2007-09-19 2009-03-26 University Health Network Methods and compositions for treating tumors and viral infections
WO2009052454A2 (en) 2007-10-19 2009-04-23 University Of California Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
EP2219458B1 (en) 2007-11-08 2015-07-15 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
GB0724231D0 (en) 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
AU2009255357A1 (en) 2008-05-29 2009-12-10 Bristol-Myers Squibb Company Methods for predicting patient response to modulation of the co-stimulatory pathway
WO2010022227A1 (en) 2008-08-20 2010-02-25 Schering Corporation Methods for monitoring il-10 therapy
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
JP5888980B2 (ja) * 2008-12-17 2016-03-22 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. モノ−およびジ−pegil10の製造および用途
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
US8435516B2 (en) 2009-10-12 2013-05-07 Pfizer Inc. Cancer treatment
BR112012009450A2 (pt) 2009-10-30 2017-05-23 Novozymes Biopharma Dk As variantes de albumina
CA2782004A1 (en) 2009-11-30 2011-06-03 Biotest Ag Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)
KR20130088131A (ko) 2010-06-16 2013-08-07 아비에 인코포레이티드 단백질 시료들의 비교
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
WO2012004384A2 (en) 2010-07-09 2012-01-12 Affibody Ab Polypeptides
EA201390450A1 (ru) 2010-09-28 2013-07-30 Амилин Фармасьютикалс, Ллк. Полипептиды с увеличенной продолжительностью действия
PT2621515T (pt) 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
GB201018289D0 (en) 2010-10-29 2010-12-15 Biocopea Ltd Treatment of respiratory disorders
RU2688185C2 (ru) 2011-03-23 2019-05-21 Фред Хатчинсон Кэнсер Рисерч Сентер Способ и композиции для клеточной иммунотерапии
CN102145178B (zh) 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
WO2013059323A1 (en) 2011-10-18 2013-04-25 Prolynx Llc Peg conjugates of exenatide
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
US9714276B2 (en) 2012-01-26 2017-07-25 Amgen Inc. Growth differentiation factor 15 (GDF-15) polypeptides
CN104245722A (zh) 2012-02-29 2014-12-24 Ambrx公司 白细胞介素-10多肽结合物和其用途
US20150118244A1 (en) 2012-05-10 2015-04-30 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
WO2014110867A1 (zh) 2013-01-17 2014-07-24 厦门赛诺邦格生物科技有限公司 一种单一官能化的支化聚乙二醇及其修饰的生物相关物质
AU2014254019B2 (en) * 2013-04-18 2018-09-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US20160068583A1 (en) * 2013-04-24 2016-03-10 Armo Biosciences, Inc. Interleukin-10 Compositions and Uses Thereof
CA2914837A1 (en) * 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
WO2015108785A1 (en) 2014-01-15 2015-07-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP4303229A3 (en) 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer

Similar Documents

Publication Publication Date Title
JP2016530284A5 (enExample)
RU2015149387A (ru) Способы применения интерлейкина-10 для лечения заболеваний и расстройств
CY1125006T1 (el) Λιπαρα οξεα και η χρηση τους σε συνδυασμο με βιομορια
JP2017533201A5 (enExample)
EP2433650A3 (en) Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
WO2011094337A8 (en) Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
JP2014526441A5 (enExample)
WO2012050923A3 (en) Engineered polypeptides having enhanced duration of action
BR112013030977A2 (pt) composição destinada ao tratamento de diabetes, compreendendo conjugado de insulina de ação prolongada e conjugado de peptídeo insulinotrópico de ação prolongada
JP2014169326A5 (enExample)
EA201170018A1 (ru) Разагилин для изменения течения болезни паркинсона
JP2016537340A5 (enExample)
JP2015521607A5 (enExample)
JP2013507131A5 (enExample)
WO2007002516A3 (en) Improved dosage forms for movement disorder treatment
NZ593813A (en) Glucagon analogues
JP2016506727A5 (enExample)
JP2013503165A5 (enExample)
WO2007078443A3 (en) Methods of treating unwanted immune response with random copolymers
WO2021021959A3 (en) Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity
JP2016539122A5 (enExample)
JP2016515123A5 (enExample)
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
JP2016512247A5 (enExample)
JP2019528290A5 (enExample)